RIQAS (Randox International Quality Assessment Scheme) gain accreditation to ISO/IEC 17043

RIQAS (Randox International Quality Assessment Scheme) are pleased to announce our recent accreditation in accordance with ISO/IEC 17043:2010, “Conformity Assessment – General Requirements for Proficiency Testing”. All clinical laboratories that seek accreditation to ISO 15189 can now be certain that RIQAS will meet their External Quality Assessment (EQA) requirements.

ISO/IEC 17043:2010 aims to establish internationally harmonised regulations and outlines general requirements that EQA providers must comply with.  The need for ongoing confidence in the competence of laboratories is not only essential for individual laboratories but accreditation bodies and other organisations.  This new standard enables both participants and laboratory accreditation bodies to have added confidence in the following areas:

  • Design and implementation of the EQA scheme
  • Sample quality, manufacture, storage and transport
  • Statistical practices used to determine participant performance
  • Participant confidentiality
  • Operation and key functions

RIQAS is the largest global EQA (proficiency testing) scheme used internationally in over 100 countries by more than 20,000 participants.  At present there are 24 comprehensive EQA programmes available each designed with convenience, consolidation and cost savings in mind.

Flexible reporting and parameter options are available to suit the needs of all laboratory sizes and budgets. Furthermore each programme contains a combination of routine and specialised parameters enabling increased opportunity for consolidation and significant cost savings.  Principle programmes include blood gas, clinical chemistry, coagulation, cardiac, glycated haemoglobin, haematology, human urine, immunoassay, immunoassay speciality I, immunoassay speciality II, lipids, maternal screening, serology (HIV-Hepatitis), serology (ToRCH), serology (EBV), serology (syphilis), specific proteins, therapeutic drugs, urinalysis and urine toxicology.

EQA results are presented in a sophisticated yet easy to interpret, one page per parameter format.  A comprehensive summary report is also provided allowing instant identification of any poor performing parameters. All reports are emailed to up to three different email addresses and are provided within 1-3 days of the final reporting date enabling any corrective actions to be taken as soon as possible.

About Randox

Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.

For more information contact us at marketing@randox.com


    Leave a Reply

    Your email address will not be published. Required fields are marked *